News | November 16, 2024
IOL Chemicals and Pharmaceuticals posts Q2 FY25 PT at Rs. 19 Cr
Total Income in Q2 FY25 stood at Rs. 532.18 crore
Total Income in Q2 FY25 stood at Rs. 532.18 crore
The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Spread over 1.26 lakh sq ft building, the super-specialty eye hospital will perform 30,000 free eye surgeries annually for economically weaker sections
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
Subscribe To Our Newsletter & Stay Updated
